Abilify Tablet/Abilify Discmelt Dosage/Direction for Use

Schizophrenia: Adults: The recommended starting and target dose for Aripiprazole (Abilify) is 10 or 15 mg/day administered on a once-a-day schedule without regard to meals. Aripiprazole (Abilify) has been systematically evaluated and shown to be effective in a dose range of 10 to 30 mg/day, when administered as the tablet formulation; however, doses higher than 10 or 15 mg/day were not more effective than 10 or 15 mg/day. Dosage increases should generally not be made before 2 weeks, the time needed to achieve steady-state [see Pharmacology: Pharmacodynamics: Clinical Studies: Schizophrenia under Actions].
Maintenance Treatment: Maintenance of efficacy in schizophrenia was demonstrated in a trial involving patients with schizophrenia who had been symptomatically stable on other antipsychotic medications for periods of 3 months or longer. These patients were discontinued from those medications and randomized to either Aripiprazole (Abilify) 15 mg/day or placebo, and observed for relapse [see Pharmacology: Pharmacodynamics: Clinical Studies: Schizophrenia under Actions]. Patients should be periodically reassessed to determine the continued need for maintenance treatment.
Adolescents: The recommended target dose of Aripiprazole (Abilify) is 10 mg/day. Aripiprazole was studied in adolescent patients 13 to 17 years of age with schizophrenia at daily doses of 10 mg and 30 mg. The starting daily dose of the tablet formulation in these patients was 2 mg, which was titrated to 5 mg after 2 days and to the target dose of 10 mg after 2 additional days. Subsequent dose increases should be administered in 5 mg increments. The 30 mg/day dose was not shown to be more efficacious than the 10 mg/day dose. Aripiprazole (Abilify) can be administered without regard to meals [see Pharmacology: Pharmacodynamics: Clinical Studies: Schizophrenia under Actions]. Patients should be periodically reassessed to determine the need for maintenance treatment.
Switching from Other Antipsychotics: There are no systematically collected data to specifically address switching patients with schizophrenia from other antipsychotics to Aripiprazole (Abilify) or concerning concomitant administration with other antipsychotics. While immediate discontinuation of the previous antipsychotic treatment may be acceptable for some patients with schizophrenia, more gradual discontinuation may be most appropriate for others. In all cases, the period of overlapping antipsychotic administration should be minimized.
Bipolar I Disorder: Acute Treatment of Manic and Mixed Episodes: Adults: The recommended starting dose in adults is 15 mg given once daily as monotherapy and 10 mg to 15 mg given once daily as adjunctive therapy with lithium or valproate. Aripiprazole (Abilify) can be given without regard to meals. The recommended target dose of Aripiprazole (Abilify) is 15 mg/day, as monotherapy or as adjunctive therapy with lithium or valproate. The dose may be increased to 30 mg/day based on clinical response. The safety of doses above 30 mg/day has not been evaluated in clinical trials.
Pediatrics: The recommended starting dose in pediatric patients (10 to 17 years) as monotherapy is 2 mg/day, with titration to 5 mg/day after 2 days, and a target dose of 10 mg/day after 2 additional days. Recommended dosing as adjunctive therapy to lithium or valproate is the same. Subsequent dose increases, if needed, should be administered in 5 mg/day increments. Aripiprazole (Abilify) can be given without regard to meals [see Pharmacology: Pharmacodynamics: Clinical Studies: Bipolar Disorder under Actions].
Dosage Adjustments for Cytochrome P450 Considerations: Dosage adjustments are recommended in patients who are known CYP2D6 poor metabolizers and in patients taking concomitant CYP3A4 inhibitors or CYP2D6 inhibitors or strong CYP3A4 inducers (see Table 8). When the coadministered drug is withdrawn from the combination therapy, Aripiprazole (Abilify) dosage should then be adjusted to its original level. When the coadministered CYP3A4 inducer is withdrawn, Aripiprazole (Abilify) dosage should be reduced to the original level over 1 to 2 weeks. Patients who may be receiving a combination of strong, moderate, and weak inhibitors of CYP3A4 and CYP2D6 (e.g., a strong CYP3A4 inhibitor and a moderate CYP2D6 inhibitor or a moderate CYP3A4 inhibitor with a moderate CYP2D6 inhibitor), the dosing may be reduced to one-quarter (25%) of the usual dose initially and then adjusted to achieve a favorable clinical response.

Click on icon to see table/diagram/image

When adjunctive Aripiprazole (Abilify) is administered to patients with major depressive disorder, Aripiprazole (Abilify) should be administered without dosage adjustment as specified in Adjunctive Treatment of Major Depressive Disorder previously.
Dosing of Oral Solution: The oral solution can be substituted for tablets on a mg-per-mg basis up to the 25 mg dose level. Patients receiving 30 mg tablets should receive 25 mg of the solution [see Pharmacology: Pharmacokinetics under Actions].
Dosing of Orally Disintegrating Tablets: The dosing for Aripiprazole (Abilify Discmelt) Orally Disintegrating Tablets is the same as for the oral tablets [see Schizophrenia, Bipolar I Disorder, Adjunctive Treatment of Major Depressive Disorder and Irritability Associated with Autistic Disorder previously].
Other Indications of Abilify Tablet/Abilify Discmelt only: Adjunctive Treatment of Major Depressive Disorder: Adults: The recommended starting dose for Aripiprazole (Abilify) as adjunctive treatment for patients already taking an antidepressant is 2 to 5 mg/day. The recommended dosage range is 2 to 15 mg/day. Dosage adjustments of up to 5 mg/day should occur gradually, at intervals of no less than 1 week [see Pharmacology: Pharmacodynamics: Clinical Studies: Adjunctive Treatment of Major Depressive Disorder under Actions]. Patients should be periodically reassessed to determine the continued need for maintenance treatment.
Irritability Associated with Autistic Disorder: Pediatric Patients (6 to 17 years): The recommended dosage range for the treatment of pediatric patients with irritability associated with autistic disorder is 5 to 15 mg/day.
Dosing should be initiated at 2 mg/day. The dose should be increased to 5 mg/day, with subsequent increases to 10 or 15 mg/day if needed. Dose adjustments of up to 5 mg/day should occur gradually, at intervals of no less than 1 week [see Pharmacology: Pharmacodynamics: Clinical Studies: Irritability Associated with Autistic Disorder under Actions]. Patients should be periodically reassessed to determine the continued need for maintenance treatment.
Tourette's Disorder: Pediatric Patients (6 to 18 years): The recommended dosage range for Tourette's Disorder is 5 to 20 mg/day.
For patients weighing less than 50 kg, dosing should be initiated at 2 mg/day with a target dose of 5 mg/day after 2 days. The dose can be increased to 10 mg/day in patients who do not achieve optimal control of tics. Dosage adjustments should occur gradually at intervals of no less than 1 week.
For patients weighing 50 kg or more, dosing should be initiated at 2 mg/day for 2 days, and then increased to 5 mg/day for 5 days, with a target dose of 10 mg/day on day 8. The dose can be increased up to 20 mg/day for patients who do not achieve optimal control of tics. Dosage adjustments should occur gradually in increments of 5 mg/day at intervals of no less than 1 week. [see Pharmacology: Pharmacodynamics: Clinical Studies: Tourette's Disorder under Actions].
Patients should be periodically reassessed to determine the continued need for maintenance treatment.